APAC IPOs & Placements, Aequitas Research

Ethan Aw

APAC IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Jinxin Fertility / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/jinxin-fertility-group-ltd" target="_blank" data-smartkarma-citation="entities:28003:1" rel="noopener">Jinxin Fertility Co Ltd (1951 HK)</a> is looking to raise US$122m via a top-up placement. </li>
<li>Proceeds from the offering will be used to repay its outstanding convertible bond and general corporate purposes. </li>
<li>In this note, we will run the deal through our ECM framework and talk about the recent updates.</li>
</ul>



Jinxin Fertility Co Ltd (1951 HK) is looking to raise US$122m via a top-up placement. 
Proceeds from the offering will be used to repay its outstanding convertible bond and general corporate purposes. 
In this note, we will run the deal through our ECM framework and talk about the recent updates.


Jinxin Fertility Group Placement - Weak Track Record And Recent Deals Have Performed Poorly

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Bottom-Up

<ul>
<li>We have seen some positive policies released in China to support assisted reproduction. However, domestic policy support is more of a short-term catalyst and would not fundamentally change Jinxin’s prospects.</li>
<li>The number of assisted reproductive centers in China is close to supply-demand equilibrium. It’s hard to support Jinxin’s valuation expansion by relying on China market. The breakthrough point is internationalization.</li>
<li>Jinxin’s 2023 performance wouldn’t rebound largely. Investors could do short-term trade based on positive news/policy related to ARS in China.There’s no signal to support the complete reversal of share price.</li>
</ul>


We have seen some positive policies released in China to support assisted reproduction. However, domestic policy support is more of a short-term catalyst and would not fundamentally change Jinxin’s prospects.
The number of assisted reproductive centers in China is close to supply-demand equilibrium. It’s hard to support Jinxin’s valuation expansion by relying on China market. The breakthrough point is internationalization.
Jinxin’s 2023 performance wouldn’t rebound largely. Investors could do short-term trade based on positive news/policy related to ARS in China.There’s no signal to support the complete reversal of share price.


Jinxin Fertility Co Ltd (1951.HK) - Hard to Achieve Performance Reversal in 2023

Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

<ul>
<li>Jinxin Fertility is a leading IVF service provider in China. It has done a series of M&amp;A in the past two years.</li>
<li>We examine the thesis of the company for a trade into 2023.</li>
<li>We believe the company has big potential to realize its synergy post acquisition and ramp up post expansion. More favorable policy to come.</li>
</ul>


Jinxin Fertility is a leading IVF service provider in China. It has done a series of M&amp;A in the past two years.
We examine the thesis of the company for a trade into 2023.
We believe the company has big potential to realize its synergy post acquisition and ramp up post expansion. More favorable policy to come.


Fu Shou Yuan International / Equity Bottom-Up

<ul>
<li>China funeral industry has large growth potential.The total market scale would be about RMB400 billion if based on annual death toll of 10 million and per capita expenditure of RMB40,000.</li>
<li>Information asymmetry weakens the bargaining power of buyers. Administrative barriers raise the threshold of market access and weaken competition. So, related companies usually have high profitability and return on capital.</li>
<li>Changes in population structure would have a negative impact on most consumer goods, but demand of funeral industry would continue to rise. Investors would have both alpha and beta superposition.</li>
</ul>


China funeral industry has large growth potential.The total market scale would be about RMB400 billion if based on annual death toll of 10 million and per capita expenditure of RMB40,000.
Information asymmetry weakens the bargaining power of buyers. Administrative barriers raise the threshold of market access and weaken competition. So, related companies usually have high profitability and return on capital.
Changes in population structure would have a negative impact on most consumer goods, but demand of funeral industry would continue to rise. Investors would have both alpha and beta superposition.


China Funeral Industry - Investment Opportunity with Both Alpha and Beta Superposition

External broker reports(aggregated public sources), CMB International

CMB International

External broker reports(aggregated public sources)

Incorporated in Hong Kong, supported by the mainland and targeting in global market, CMB International Capital Corporation Limited (“CMBI”) is an integrated financial institution providing comprehensive and professional services. As a wholly-owned subsidiary of China Merchants Bank ("CMB"), by leveraging on the Group’s synergy and coordination in domestic and overseas markets, as well as CMB’s strong resources and outstanding social reputation, CMBI and its subsidiaries have been actively implementing diversified business strategies and set up an overall layout of main business segments including Corporate Finance, Asset Management, Wealth Management, Global Markets and Structured Finance, etc. Adhering to the philosophy of “being clients oriented and increasing our own values by the way of creating value for clients”, CMBI endeavors to provide quality and integrated financial services to institutional, corporate and individual customers both domestic and overseas including Hong Kong IPO sponsorship and underwriting, share placement and rights issue for listed companies, financial advisors, bonds issuance services, asset management, direct investment, wealth management, equity sales and trading, etc.

<ul><li>1H22 earnings impacted by COVID restrictions. Jinxin reported 1H22 revenue of RMB1,138mn, up 33% YoY, attributable net income of RMB190mn, up 22% YoY, and adjusted Non-IFRS attributable net income of RMB261mn, up 18% YoY.</li><li>Earnings slightly missed our forecasts, mainly due to the negative impact from COVID-19 outbreaks in Shenzhen and Chengdu.</li><li>Revenue from Chengdu increased by 71% YoY thanks to business consolidation of Jinxin Women and Children Hospital (WCH). Excluding WCH, revenue from Chengdu realized single-digit growth, per management.</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

1H22 earnings impacted by COVID restrictions. Jinxin reported 1H22 revenue of RMB1,138mn, up 33% YoY, attributable net income of RMB190mn, up 22% YoY, and adjusted Non-IFRS attributable net income of RMB261mn, up 18% YoY.Earnings slightly missed our forecasts, mainly due to the negative impact from COVID-19 outbreaks in Shenzhen and Chengdu.Revenue from Chengdu increased by 71% YoY thanks to business consolidation of Jinxin Women and Children Hospital (WCH). Excluding WCH, revenue from Chengdu realized single-digit growth, per management.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Jinxin Fertility (1951 HK) – Resilient Business Amid COVID Pandemic

China

Jinxin Fertility Group is a leading international provider of assisted reproductive services (ARS) and assisted reproductive technology (ART). Its core offerings include In Vitro Fertilization (IVF), Intrauterine Insemination (IUI), egg retrieval, embryo transfer, and genetic screening, alongside a range of women's health services. The company is headquartered in Chengdu, China, and was founded in 1951.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Jinxin Fertility (1951 HK)

Jinxin Fertility Group Placement - Weak Track Record And Recent Deals Have Performed Poorly

Jinxin Fertility Co Ltd (1951 HK) is looking to raise US$122m via a top-up placement. Proceeds from the offering will be used to repay its...

Ethan Aw

Jinxin Fertility Co Ltd (1951.HK) - Hard to Achieve Performance Reversal in 2023

The growth ceiling in China is obvious, which cannot support Jinxin’s valuation expansion.The breakthrough point is internationalization,...

Xinyao (Criss) Wang

2023 High Conviction: Jinxin Fertility

Jinxin Fertility is a leading IVF service provider in China. It has done a series of M&A in the past two years. We examine the thesis of the...

Ke Yan, CFA, FRM

China Funeral Industry - Investment Opportunity with Both Alpha and Beta Superposition

Death is inevitable, which provides continuous demand for China funeral industry. Related companies have high return on capital. investors will...

Xinyao (Criss) Wang

Jinxin Fertility (1951 HK) – Resilient Business Amid COVID Pandemic

Earnings slightly missed our forecasts, mainly due to the negative impact from COVID-19 outbreaks in Shenzhen and Chengdu.

CMB International

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)